Telomir Pharmaceuticals, Inc. (TELO)
↓ Download CSVKey ratios (FY2025)
-176.1%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$10.41M | -$16.53M | -$13.07M | -$854.1K | — |
| EPS (Diluted) | $-0.33 | $-0.56 | $0.48 | $-0.03 | — |
| Total Assets | $7.34M | $1.32M | $4.77M | $48.7K | — |
| Total Liabilities | $1.43M | $681.0K | $1.34M | $986.0K | — |
| Shareholders' Equity | $5.91M | $643.0K | $3.44M | -$937.3K | -$138.1K |
| Operating Cash Flow | -$3.69M | -$5.07M | -$3.86M | -$468.7K | — |
| Shares Outstanding | 34.38M | 29.76M | 28.61M | 26.83M | — |